12 October 2022
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Grant of Options and PDMR/director shareholdings
Proteome Sciences announces the grant of options over new ordinary shares of 1p each in the Company ("Ordinary Shares") under the Company's share option schemes ("Options"). A total of 3,000,000 Options were yesterday issued to two directors of the Company.
Details of the Options granted to directors are outlined in the table below:
| Name of Director | Number of Options Granted | Total number of options now held |
| Dr Ian Pike | 1,500,000 | 4,000,000 |
| Mr Richard Dennis | 1,500,000 | 4,000,000 |
The Options are exercisable at the closing price of the Company's Ordinary Shares' yesterday, being 4.3 pence per Option. For Dr Ian Pike and Mr Richard Dennis, the Options will vest in three tranches as to 500,000 on 11 October 2023, 500,000 on 11 October 2024 and 500,000 on 11 October 2025. Options have also been awarded to other employees totaling 2,520,000. Each Option is exercisable into one Ordinary Share and once vested, can be exercised up until the 10th anniversary of yesterday's date.
The Options granted yesterday represent approximately 1.87 per cent of the Company's current issued share capital. In total 20,534,000 Options are now outstanding, representing approximately 6.96 per cent of the Company's current issued share capital.
Further details and the information required in accordance with the requirements of Article 19(3) of the Market Abuse Regulation No 596/2014 (as retained and applicable in the UK pursuant to section 3 of the European Union (Withdrawal) Act 2018) ("UK MAR") are set out at the end of this announcement.
For further information:
| Proteome Sciences plc Dr Mariola Soehngen, Chief Executive Officer Abdelghani Omari, Chief Financial Officer Dr Ian Pike, Chief Scientific Officer
| Tel: +44 (0)20 7043 2116 |
| Allenby Capital Limited (AIM Nominated Adviser & Broker) John Depasquale / Jeremy Porter
| Tel: +44 (0) 20 3328 5656 |
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
The Company has its headquarters in Cobham, UK, with laboratory facilities in Frankfurt, Germany.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
The below notification is made in accordance with the requirements of UK MAR.
1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name: | Ian Pike | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status: | Chief Scientific Officer | ||||
| b) | Initial notification/Amendment: | Initial Notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name: | Proteome Sciences Plc | ||||
| b) | LEI: | 213800Q62ICXANKU2986 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary Shares of 1p nominal value GB0003104196 | ||||
| b) | Nature of the transaction: | Grant of options under the Proteome Sciences plc 2011 Long Term Share Incentive Plan to acquire ordinary shares of 1p each in Proteome Sciences plc | ||||
| c) | Price(s) and volume(s): |
| ||||
| d) | Aggregated information: · Aggregated volume: · Price: | Single transaction as in c) above
| ||||
| e) | Date of the transaction: | 11 October 2022 | ||||
| f) | Place of the transaction: | N/A | ||||
1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name: | Richard Dennis | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status: | Chief Commercial Officer | ||||
| b) | Initial notification/Amendment: | Initial Notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name: | Proteome Sciences Plc | ||||
| b) | LEI: | 213800Q62ICXANKU2986 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary Shares of 1p nominal value GB0003104196 | ||||
| b) | Nature of the transaction: | Grant of options under the Proteome Sciences plc 2011 Long Term Share Incentive Plan to acquire ordinary shares of 1p each in Proteome Sciences plc | ||||
| c) | Price(s) and volume(s): |
| ||||
| d) | Aggregated information: · Aggregated volume: Price: | Single transaction as in c) above
| ||||
| e) | Date of the transaction: | 11 October 2022 | ||||
| f) | Place of the transaction: | N/A | ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
